Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.57.
VSTM has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Verastem in a research note on Friday. Truist Financial cut their price target on shares of Verastem from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Verastem in a research note on Friday. StockNews.com raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Finally, B. Riley reduced their price target on Verastem from $21.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, July 24th.
Read Our Latest Research Report on VSTM
Institutional Inflows and Outflows
Verastem Trading Up 11.3 %
Shares of NASDAQ:VSTM opened at $2.96 on Monday. The company’s 50-day moving average price is $2.67 and its two-hundred day moving average price is $5.06. Verastem has a one year low of $2.10 and a one year high of $14.22. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.28 and a quick ratio of 3.28. The stock has a market capitalization of $119.11 million, a PE ratio of -0.89 and a beta of 0.17.
Verastem (NASDAQ:VSTM – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.75. The company had revenue of $10.00 million during the quarter. On average, equities analysts forecast that Verastem will post -3.36 EPS for the current fiscal year.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Recommended Stories
- Five stocks we like better than Verastem
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is MarketRankā¢? How to Use it
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Using the MarketBeat Dividend Yield Calculator
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.